ProKidney Corp Dossier - Source-backed chat

ProKidney Corp

PROKNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.51

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.71Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $682.6M

Enterprise Value $607.7M

Shares Outstanding 399.2M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

ProKidney Corp. is a late clinical-stage biotechnology company pioneering rilparencel (REACT), a first-in-class autologous cell therapy designed to preserve kidney function in patients with advanced chronic kidney disease (CKD) and type 2 diabetes. The investment thesis is anchored on a highly de-risked regulatory pathway, following FDA alignment that the annualized eGFR slope from the ongoing Phase 3 PROACT 1 trial can serve as the surrogate endpoint for accelerated approval. With positive Phase 2 REGEN-007 data published in early 2026 showing significant slowing of eGFR decline, and a cash runway extending into mid-2027, ProKidney is well-positioned to reach its pivotal Q2 2027 topline readout. Successful clinical execution would address a massive unmet medical need, potentially delaying or preventing the need for dialysis for millions of patients.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets6 analysts · as of 18 Aug 2026

Low · most bearish analyst$1.00

Mean target$6.25

High · most bullish analyst$12.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.0820%

The Phase 3 PROACT 1 trial fails to meet the FDA-agreed efficacy threshold for eGFR slope improvement, or safety concerns arise regarding the percutaneous injection procedure. Given ProKidney's single-asset focus, clinical failure or a major regulatory delay would severely impair the company's valuation and force a dilutive restructuring.

Base CaseCentral scenario

$5.7555%

The Phase 3 PROACT 1 trial successfully demonstrates a statistically significant and clinically meaningful eGFR slope improvement of at least 1.5 mL/min/1.73m²/year versus sham control in Q2 2027. This supports a BLA submission under the accelerated approval pathway, with the stock re-rating closer to consensus analyst targets as regulatory risk decreases.

Bull CaseUpside scenario

$12.0025%

The Phase 3 PROACT 1 trial meets its primary surrogate endpoint in Q2 2027 with an eGFR slope improvement significantly exceeding the FDA's 1.5 mL/min/1.73m²/year threshold. Rilparencel receives accelerated approval from the FDA by late 2028, capturing a dominant share of the advanced diabetic CKD market due to its disease-modifying profile and lack of direct cell-therapy competitors.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

FDA alignment on an accelerated approval pathway using eGFR slope as a surrogate endpoint, significantly shortening the timeline to potential commercialization.
Strong clinical proof-of-concept from the Phase 2 REGEN-007 trial, which demonstrated a statistically significant slowing of eGFR decline.
First-in-class autologous cell therapy platform with robust global patent protection and an in-house GMP-aligned manufacturing facility.
Sufficient cash runway ($224.9M as of Q1 2026) to fund operations into mid-2027, covering the critical Q2 2027 pivotal topline data readout.

Key Investment Risks

Single-asset risk: ProKidney's pipeline is heavily reliant on the clinical and regulatory success of rilparencel.
Clinical trial execution risk: Any delays in completing PROACT 1 enrollment or unexpected safety signals could push back the Q2 2027 readout.
Funding risk: The current cash runway extends only into mid-2027, meaning the company will likely need to raise capital near or shortly after the topline data release.
Commercialization and adoption hurdles: As a personalized autologous cell therapy requiring kidney biopsies and specialized processing, rilparencel faces complex logistics and market entry challenges.

Thesis Invalidation Triggers

Failure of the Phase 3 PROACT 1 trial to achieve an eGFR slope improvement of at least 1.5 mL/min/1.73m²/year versus sham control.
Severe or unexpected adverse events related to the percutaneous kidney injection procedure or the cell therapy itself.
A material delay in completing trial enrollment that pushes the pivotal topline readout past 2027.
Inability to secure additional financing on reasonable terms, leading to severe dilution or a going-concern warning before the Q2 2027 data readout.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.